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Abstract
In this study, we used oligonucleotide microarray analysis to determine which cellular genes are regulated by the human papillomavirus
type 16 (HPV-16) E6 oncoprotein. We found that E6 causes the downregulation of a large number of cellular genes involved in keratinocyte
differentiation, including genes such as small proline-rich proteins, transglutaminase, involucrin, elafin, and cytokeratins, which are
normally involved in the production of the cornified cell envelope. In contrast, E6 upregulates several genes, such as vimentin, that are
usually expressed in mesenchymal lineages. E6 also modulates levels of genes involved in inflammation, including Cox-1 and Nag-1. By
using E6 mutants that differentially target p53 for degradation, we determined that E6 regulates cellular genes by both p53-dependent and
independent mechanisms. The microarray data also indicate that HPV-16 E6 modulates certain effects of HPV-16 E7 on cellular gene
expression. The identification of E6-regulated genes in this analysis provides a basis for further studies on their role in HPV infection and
cellular transformation.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Human papillomaviruses (HPVs) are small, double-
stranded DNA viruses that infect epithelial tissues and in-
duce hyperproliferative lesions (Howley, 1995). While
HPVs infect proliferating basal cells, viral production is
associated with terminally differentiated layers of the epi-
thelium. Thus, cellular differentiation and virus production
are tightly linked. More than 85 distinct types of HPV have
been identified and categorized into different risk groups
(zur Hausen, 2000). Members of the “low-risk” group in-
duce common warts, members of the “intermediate-risk”
group induce anogenital warts, and members of the “high-
risk” group are associated with anogenital tract lesions that
can progress to malignancy (zur Hausen, 1991). High-risk
HPV nucleic acids are detected in 90% of cervical carcino-
mas and HPV-16 is the predominate member of this group
(Howley, 1991).
E6 and E7 are the major transforming proteins of high-
risk HPV types and are known to alter cellular differentia-
tion (Alfandari et al., 1999; Sherman and Schlegel, 1996),
reactivate host DNA synthesis (Cheng et al., 1995), and
stimulate cell-cycle progression (Woodworth et al., 1992).
Expression of E6 and E7 has also been shown to downregu-
late expression of genes involved in immune responses such
as interferon-inducible genes (Chang and Laimins, 2000,
2001; Nees et al., 2001). E6 and E7 are thought to perturb
cellular gene expression by interfering with the functions of
cellular regulatory proteins. HPV E7 is known to bind
hypophosphorylated retinoblastoma protein (pRb) (Dyson
et al., 1989; Munger et al., 1989), causing increased levels
of active E2F transcription factors. This results in increased
expression of genes involved in cell-cycle progression and
DNA synthesis. HPV-16 E6 binds a number of cellular
proteins including the E6-associated protein (E6AP), a pro-
tein-ligase of the ubiquitin proteolysis pathway (Rapp and
Chen, 1998). E6 complexed with E6AP targets the p53
tumor suppressor protein for proteasome degradation
(Scheffner et al., 1990). The p53 protein is a central tran-
* Corresponding author. Fax: 1-319-335-9006.
E-mail address: Al-Klingelhutz@uiowa.edu (A.J. Klingelhutz).
R
Available online at www.sciencedirect.com
Virology 314 (2003) 196–205 www.elsevier.com/locate/yviro
0042-6822/03/$ – see front matter © 2003 Elsevier Science (USA). All rights reserved.
doi:10.1016/S0042-6822(03)00390-8
scription factor important in the regulation of cellular re-
sponses to stress and DNA damage, and loss of p53 leads to
genetic instability and progression toward malignancy
(Vousden and Lu, 2002). One key downstream effector of
p53 is p21Waf/Cip (hereafter referred to as p21), a cdk/cyclin
inhibitor whose upregulation by p53 leads to cell-cycle
arrest (El-Deiry et al., 1993). Interestingly, p21 has been
linked to differentiation of keratinocytes (Harvat et al.,
1998; Missero et al., 1996). In addition to its role in p53
degradation, HPV-16 E6 has been shown to bind to numer-
ous other cellular proteins including several transcription
factors (Mantovani and Banks, 2001). It has been shown
that HPV-16 E6 has several p53-independent functions that
are likely to play a role in the immortalization and the
development of malignancy. For example, overexpression
of HPV-16 E6 by retroviral-mediated transduction has been
shown to activate telomerase by a mechanism that does not
rely on p53 degradation (Klingelhutz et al., 1996). While
both E6 and E7 are required for HPV-mediated cellular
immortalization, E6 is the primary activator of telomerase
and is known to increase transcription of the catalytic sub-
unit of telomerase (hTERT) (Gewin and Galloway, 2001;
Klingelhutz et al., 1996; Oh et al., 2001; Veldman et al.,
2001).
In the present study, we used oligonucleotide array anal-
ysis of mRNA levels from cells coexpressing HPV-16 E7
with variants of HPV-16 E6 with the aim of identifying
genes regulated by E6 that may play a role in cellular
transformation and/or the viral life cycle. Our analysis
showed that a large number of the genes downregulated by
E6 are involved in keratinocyte differentiation and the for-
mation of the cornified barrier. We also identified a number
of other genes that were regulated by E6 in both p53-
dependent and p53-independent manners. The identification
of cellular genes regulated by E6 should be useful in un-
derstanding the role of E6 in infection and malignant pro-
gression of HPV-associated lesions.
Results
Establishment and characterization of cells for
microarray analysis
A goal of this study was to identify cellular genes regu-
lated by expression of HPV-16 E6 that may play a role in
the HPV life cycle or in cellular transformation. To generate
a sufficient number of cells for microarray analysis and
subsequent validation, we decided to first extend cellular
lifespan by expression of HPV-16 E7. HPV-16 E7 express-
ing keratinocytes were generated by infecting normal pri-
mary cells with an LXSH retrovirus that expressed E7 and
conferred hygromycin resistance. After selection in hygro-
mycin, cells were infected with an LXSN retroviral con-
struct that expressed wild-type HPV-16 E6 and conferred
G418 resistance. Because we wanted to determine if regu-
lation of genes by E6 was dependent on p53 degradation or
associated with telomerase activation, we also infected E7
keratinocytes with LXSN retroviruses that expressed
HPV-16 E6 variants, 118–122 and 8S9A10T, that have
been shown to be defective in telomerase activation and
targeting of p53 for degradation, respectively. Doubly in-
fected cells were selected with G418. Western analysis
using a p53-specific antibody demonstrated that keratino-
cytes that coexpressed E7 with wild-type E6 had degraded
p53 as compared to E7 expressing cells infected with vector
alone (Fig. 1). Cells coexpressing E7 with the E6 mutants,
E6 118–122, or E6 8S9A10T exhibited partial and no
degradation of p53, respectively (Fig. 1). An ELISA-based
telomeric repeat amplification protocol (TRAP) analysis
showed the cells expressing wild-type E6 or the 8S9A10T
mutant had active telomerase, whereas cells expressing vec-
tor alone or the 118–122 mutant did not. These results are
similar to those reported previously (Foster et al., 1994;
Klingelhutz et al., 1996). The 118–122 E6 mutant has
been shown to have a decreased ability to target p53 for
degradation and this is more apparent in the context of E7
expression. Reverse-transcriptase polymerase chain reac-
Fig. 1. Characterization of cells used for microarray studies. Top: ELISA-
based telomerase activity assay. Values represent absorbance units as
measured by an ELISA plate reader; middle: RT-PCR for hTERT and 18S
control; bottom: Western analysis for p53 protein. Lanes are as follows:
vector E7, keratinocytes infected with the retroviral construct HPV-16
E7-LXSH and LXSN empty vector; 16E6 E7, keratinocytes infected with
HPV-16 E7-LXSH and HPV-16 E6-LXSN; 118–122 E6 E7, keratino-
cytes infected with HPV-16 E7-LXSH- and an LXSN-based retrovirus
expressing the HPV-16 E6 mutant 118–122; 8S9A10T E6 E7, keratin-
ocytes infected with HPV-16 E7-LXSH, and an LXSN-based retrovirus
expressing the HPV-16 E6 mutant 8S9A10T.
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tion (RT-PCR) analysis for hTERT expression demon-
strated that hTERT was upregulated in association with
telomerase activity in cells expressing the wild-type E6 and
8S9A10T E6 mutant. Thus, the generated cell lines exhib-
ited the expected phenotypes and were used for subsequent
analyses.
Oligonucleotide array analysis of mRNA levels in cells
expressing HPV-16 E6 and E7
To identify genes that are up- or downregulated by
HPV-16 E6, we used Affymetrix gene arrays. Steady-state
mRNA levels from four cells types (i.e., HFKs expressing
E7 and E6 wild-type, E7 and E6 118–122, E7 and E6
8S9A10T, and E7 alone) were analyzed with Affymetrix
oligonucleotide arrays (HuFL) that contained probes to
5600 different human genes. Raw data were analyzed with
the Affymetrix GENECHIP software package. The oligo-
nucleotide array experiments were performed twice with
independently derived cell lines from different keratinocyte
donors. We first sorted the data for genes that were up- or
downregulated by coexpression of E7 and wild-type E6 as
compared to expression of E7 alone. Our sort criteria se-
lected genes that the Affymetrix GENECHIP software iden-
tified as Increased or Decreased and had a more than two-
fold change in mRNA levels. This sort indicated that wild-
type E6 caused up- or downregulation of at least 54 genes
by two- or more fold. These included genes that were
involved in cell structure and differentiation, cell-cycle and
DNA damage response, angiogenesis, inflammation and im-
mune response, metabolism, and signal transduction (Table
1). Because p53 upregulates expression of the cdk/cyclin
inhibitor p21, we anticipated that cells expressing wild-type
E6 and concomitant degradation of p53 would have lower
levels of p21. As expected, p21 transcript was downregu-
lated by fourfold in cells that expressed wild-type E6 and E7
together as compared to E7 alone but not in cells that
expressed the E6 mutants that did not target p53 for degra-
dation (Table 1, line 27). This finding was validated by both
Northern and Western analyses (Fig. 2).
Expression of E6 downregulated a large number of genes
involved in keratinocyte differentiation (Table 1, lines 1 to
20), including several genes such as small proline-rich pro-
tein genes, elafin, stratum corneum chymotryptic enzyme,
involucrin, and keratinocyte transglutaminase, that play a
role in the formation of the cornified envelope (Kalinin et
al., 2002). Most of these genes were downregulated regard-
less of p53 status. The downregulation of two of these
genes, SPRR1A and chondroitin sulfate proteoglycan ver-
sican (CSPV), was validated by Northern and RT-PCR
analyses (Figs. 3 and 4).
Interestingly, E6 upregulated a number of genes that are
normally expressed in mesenchymal lineages. For example,
tenascin-C, neurofilament heavy chain, vimentin (Table 1,
lines 24–26), and mesoderm specific transcript (MEST,
Table 1, line 46) were all upregulated. Vimentin and MEST
upregulation by E6 was validated by Northern analysis
(Figs. 3 and 5a). In the case of MEST, both the microarray
and the Northern analyses indicated that MEST transcripts
were upregulated by wild-type E6 and 8S9A10T E6 but not
by 118–122 E6, indicating that upregulation of MEST
was independent of p53 degradation (Fig. 3). Similarly, the
microarray analysis indicated that wild-type E6 and
8S9A10T E6, but not 118–122 E6, upregulated vimentin
transcript levels (Table 1, line 26). Northern analysis for
vimentin expression, however, suggested that the 118–
122 E6 mutant also upregulated vimentin but to a lesser
extent than was observed for wild-type E6 or 8S9A10T E6
(Fig. 5a). The reason for the discrepancy between the mi-
croarray and Northern analyses is unknown. The results
from Western analysis for vimentin were more similar to the
microarray results (Fig. 5b).
As has been shown previously, E6 also downregulated
several genes involved in immune response (Table 1, lines
33–38) (Chang and Laimins, 2000, 2001; Nees et al., 2001).
Wild-type E6 downregulated a gene, Nag-1, that is a mem-
ber of the TGF- superfamily and is known to be involved
in an anti-inflammatory response (Table 1, line 31), but
upregulated eight-fold the inflammation associated gene,
cox-1, which is involved in prostaglandin synthesis (Table
1, line 32) (Baek et al., 2002). In the case of cox-1, the
microarray data indicated that the E6 mutants did not alter
expression. However, RT-PCR analysis demonstrated that
both the wild-type and the mutants upregulated expression
(Fig. 4), thus signifying the necessity of validating the
microarray results by performing an independent assay to
examine gene expression. The microarray analysis did not
indicate downregulation of Stat1, as has been reported pre-
viously (Chang and Laimins, 2000). E6 or E7 regulation of
Stat1 protein levels or phosphorylation was also not ob-
served by Western analysis (Fig. 5b).
Conspicuously absent from the microarray data is
hTERT, the reverse transcriptase component of telomerase,
that was included on the microarray and was shown to be
upregulated by wild-type E6 and 8S9A10T by RT-PCR
analysis. The reason for this discrepancy is unknown, but
because hTERT is expressed at low levels even in telom-
erase-positive cells (Meyerson et al., 1997; Nakamura et al.,
1997), the microarray analysis was probably not sensitive
enough to detect the transcript. This latter observation in-
dicates that microarray analysis may not be an ideal method
to examine changes in transcripts that are expressed at low
levels.
Differential regulation of genes by E6 and E7
In general, E6 and E7 are thought to be expressed simul-
taneously in HPV-infected cells. Therefore, we decided to
compare array data from cells that expressed E6 and E7
together to array data from normal keratinocytes that ex-
pressed vector (LXSN) alone. The microarray data from
cells that expressed E7 alone were compared to data from
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Table 1
Genes regulated by HPV-16 E6
Line Accession
No.
Description Fold changesa
E6/E7
vs E7b
118-122E6/E7
vs E7
8S9A10T
E6/E7 vs E7
E6/E7
vs vector
E7 vs
vector
Cell structure/differentiation
1 L00205 K6b (epidermal keratin, type II) 4.0 1.3 1.3 13.0 3.1
2 L05187 Small proline-rich protein 1 (SPRR1A) 3.0 1.2 2.5 8.5 2.7
3 L05188 Small proline-rich protein 2 (SPRR2B) 4.0 1.3 2.8 3.7 1.2
4 L10343 Elafin 4.0 1.1 2.7 13.0 2.7
5 L33404 Stratum corneum chymotryptic enzyme 23.0 2.9 20.0 50.0 1.0
6 M13903 Involucrin 6.0 2.3 5.6 14.0 2.8
7 M18728 Nonspecific crossreacting (carcinoembryonic) antigen 5.0 5.2 4.6 2.8 2.3
8 M20030 Small proline-rich protein (SPRRII), SPRR2E 4.0 1.1 3.4 4.9 1.4
9 M26311 Cystic fibrosis antigen (Calgranulin B, S100A9) 7.0 1.1 1.6 14.0 2.2
10 M98447 Keratinocyte transglutaminase 5.0 2.1 2.6 3.3 1.5
11 U16306 Chondroitin sulfate proteoglycan versican VO 32.0 16.8 1.9 1.7 11.0
12 U65932 Extracellular matrix protein 1 (ECM1) 3.0 2.3 2.7 3.9 1.4
13 U92314 Hydroxysteroid sulfotransferase SULT2B1a (HSST2) 11.0 7.6 2.1 5.6 2.8
14 X07695 Cytokeratin 4 4.0 1.5 3.5 7.5 1.9
15 X07696 Cytokeratin 15 3.0 3.1 3.5 2.6 1.3
16 X13839 Vascular smooth muscle -actin 7.0 12 1.2 1.7 7.0
17 X52426 Cytokeratin 13 4.2 1.3 21.0 36.0 1.6
18 X53065 SPR2-1 (small proline-rich protein) 3.0 1.4 2.8 2.7 1.3
19 X82693 E48 antigen 3.0 1.8 1.3 5.3 2.0
20 Y00503 Keratin 19 10.0 4.7 2.6 24.0 2.4
21 J03040 Human SPARC/osteonectin 3.0 2.1 1.3 2.2 1.4
22 L27624 Tissue factor pathway inhibitor-2 2.0 1.3 1.6 1.4 1.7
23 M19309 Slow skeletal muscle troponin T 5.0 1.1 2.1 1.4 7.1
24 X15306 NF-H (neurofilament-heavy) 4.0 1.4 1.2 11.0 2.3
25 X78565 Tenascin-C 4.0 1.2 1.3 1.7 2.5
26 Z19554 Vimentin 4.0 1.1 4.4 1.1 3.9
Cell cycle/proliferation/DNA damage
27 U09579 p21CIP/WAF, melanoma differentiation associated 4.0 1.0 1.1 2.0 1.2
28 U18300 Damage-specific DNA binding protein p48 subunit 2.0 1.5 1.2 1.2 2.0
Angiogenesis
29 U43142 Vascular endothelial growth factor related protein VRP 3.0 2.5 1.9 3.1 1.4
30 X54936 Placenta growth factor (PIGF) 6.0 3.8 1.3 3.0 2.2
Inflammatory/immune response
31 AB000584 TGF  superfamily protein (Nag-1) 18.0 12.0 1.6 1.8 7.6
32 M59979 Prostaglandin endoperoxide synthase (Cox-1) 8.0 1.4 1.4 9.2 1.0
33 K03021 Tissue plasminogen activator (PLAT) 8.0 9.8 8.9 1.9 6.5
34 M93056 Monocyte/neutrophil elastase inhibitor 5.0 3.4 1.1 1.2 8.7
35 S75256 HNL (neutrophil lipocalin) 7.0 4.0 6.5 3.5 2.4
36 X53296 IRAP 3.0 1.8 2.0 4.2 1.5
37 X82200 Staf50 4.0 1.3 1.4 2.1 2.0
38 X99133 NGAL 29.0 4.0 9.3 8.0 3.2
Metabolism
39 X01630 Argininosuccinate synthesis 5.0 1.5 2.2 2.9 1.5
40 X05409 Mitochondrial aldehyde dehydrogenase I (ALDH I) 7.0 1.3 1.9 6.0 1.7
Signal transduction
41 HG162 Tyrosine kinase, Receptor Axl, Alt. splice 2 2.0 1.3 1.2 1.7 1.4
42 L24564 Rad 31.0 6.1 4.9 5.1 4.9
43 M62404 Insulin-like growth factor binding protein 6 (IGFBP6) 4.6 1.3 3.4 1.4 4.0
44 U52101 YMP 3.0 1.1 3.1 1.5 4.8
45 U57650 SH2-containing inositol 5-phosphatase (hSHIP) 8.0 2.4 1.1 3.1 2.6
(continued on next page)
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cells that expressed vector alone to determine how expres-
sion of E7 alone affected transcript levels. Again, the array
experiments were performed twice with independently de-
rived LXSN-, E7-, or E6/E7-expressing cells from different
HFK cell strains.
In most cases, the genes that were up- or downregulated
by E6/E7 as compared to E7 alone were also found to be up-
or downregulated in a similar fashion by E6/E7 as compared
to vector alone (Table 1). For many genes, a more dramatic
effect was observed when comparing E6/E7 cells to vector
alone cells as opposed to comparison of E6/E7 cells to E7
alone cells. For example, expression of SPRRIA was re-
duced 3.0-fold in E6/E7-expressing cells as compared to
E7-expressing cells but was reduced 8.5-fold as compared
to cells that contained vector alone (Table 1, line 2). For
several genes, the data indicated that E7 caused a change in
transcript levels in one direction, whereas concomitant ex-
pression of E6 caused a change in transcript levels in the
opposite direction. A good example to illustrate this point is
the gene vimentin (Table 1, line 26). In this particular case,
E7 downregulated expression by 3.9-fold as compared to
vector only keratinocytes. Concomitant expression of E6
upregulated expression by 4.0-fold, with a net effect of
Table 1 (continued)
Line Accession
No.
Description Fold changesa
E6/E7
vs E7b
118-122E6/E7
vs E7
8S9A10T
E6/E7 vs E7
E6/E7
vs vector
E7 vs
vector
Miscellaneous
46 D78611 MEST 6.0 1.3 2.5 2.5 2.6
47 HG4185 Estrogen sulfotransferase 2.0 1.8 1.4 1.2 1.7
48 L49054 t(3;5)(q25.1;p34) fusion gene NPM-MLF1 4.0 2.7 2.8 2.3 1.8
49 M32053 H19 17.0 2.9 1.8 1.4 12.0
50 AC000115 WUGSC:H_GS188P18.1a 3.0 4.2 13.0 3.8 1.8
51 U62801 Protease M 16.0 1.4 29.0 7.9 1.8
52 U69546 RNA binding protein Etr-3 10.0 3.6 1.7 6.3 2.7
53 U72661 Ninjurin 1 4.0 6.4 3.6 1.0 3.0
54 Y00339 Carbonic anhydrase II (EC 4.2.1.1) 4.0 1.2 2.9 1.6 3.4
a Average of two experiments.
b Genes are listed that were altered by two or more fold and called “increased” or “decreased” by Affymetrix GeneChip Software in two independent
comparisons of E6/E7 vs E7 expressing cells. The number shown represents the average fold change of the two comparisons. Negative values represent a
decrease whereas positive values represent an increase.
Fig. 2. (a) Northern blot to determine levels of p21Cip/Waf transcripts. A
36B4 probe was used for a control. Lanes are the same as in Fig. 1. (b)
Western blot for p21Cip/Waf protein expression. An antibody for -actin
was used as a control. Lanes are the same as in Fig. 1.
Fig. 3. Northern blot to determine levels of MEST and SPRRIA transcripts.
A 36B4 probe was used as a control. Lanes are the same as in Fig. 1.
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1.1-fold upregulation when comparing E6/E7 keratinocytes
to vector-only keratinocytes. A Western analysis using a
vimentin antibody confirmed these observations and also
indicated that the effect on vimentin expression was inde-
pendent of p53 degradation (Fig. 5b). These results suggest
that the regulation of some cellular genes by E7 is moder-
ated by expression of E6.
Discussion
In this study we have identified genes that are regulated
by expression of HPV-16 E6 in human keratinocytes. We
found by microarray analysis that at least 54 genes were up-
or downregulated twofold or more by expression of E6 in
the context of E7 expression. Although some alterations in
gene expression (e.g., p21) were dependent on p53 degra-
dation, many others were not. This data provide further
evidence that HPV-16 E6 exerts many of its effects inde-
pendently of p53.
One of the initial objectives of this study was to identify
genes that might play a role in upregulation of hTERT and
telomerase activation by E6. This goal was modified, how-
ever, when it was observed that the microarrays were not
sensitive enough to detect alterations in hTERT levels in
cells that expressed E6. An inference from this result is that
changes in cellular genes that affect hTERT expression may
also not be picked up by the microarrays. Nevertheless, a
number of interesting E6-regulated genes were identified in
this analysis.
Many of the genes that were downregulated by E6 are
genes that encode proteins involved in keratinocyte differ-
entiation. This downregulation was observed when E6 and
E7 were coexpressed, either when compared to expression
profiles of cells that contained vector alone or E7 alone. The
E6 mutant, 8S9A10T, that did not target p53 for degradation
also caused downregulation of many of the same genes,
indicating that the mechanism of downregulation by E6 is
independent of p53 degradation. The reason that HPV
downregulates genes involved in keratinocyte differentia-
tion is not completely clear. It has been demonstrated by
others that HPV-16 E6 inhibits serum- and calcium-induced
differentiation of human keratinocytes (Sherman and Schle-
gel, 1996). Our results identify several of the genes that may
be involved in this process. A previous study using microar-
rays showed evidence that E6 and E7 may affect differen-
tiation through downmodulating the transforming growth
factor- (TGF-) pathway (Nees et al., 2000). In our stud-
ies, we did not observe downregulation of either TGF-
isoforms or TGF- receptors. The reason for this discrep-
Fig. 5. (a) Northern blot to determine levels of vimentin transcripts. A
36B4 probe was used as a control. Lanes are the same as in Fig. 1. (b)
Western blot to determine levels of vimentin and Stat1 protein in cells.
Stat1 exists in phosphorylated (top band) and unphosphorylated (bottom
band) forms. Lanes are as follows: vector E7, keratinocytes infected with
HPV-16 E7-LXSH and LXSN empty vector; 16E6 E7, keratinocytes in-
fected with the retroviral construct HPV-16 E7-LXSH and HPV-16 E6-
LXSN; 118–122 E6 E7, keratinocytes infected with HPV-16 E7-LXSH
and an LXSN-based retrovirus expressing the HPV-16 E6 mutant 118–
122; 8S9A10T E6 E7, keratinocytes infected with HPV-16 E7-LXSH and
an LXSN-based retrovirus expressing the HPV-16 E6 mutant 8S9A10T;
vector, keratinocytes infected with empty vector LXSN alone; 16E6, ker-
atinocytes infected with HPV-16 E6-LXSN alone. A Western for actin was
performed to ensure equal loading and protein integrity.
Fig. 4. RT-PCR for chondroitin sulfate proteoglycan versican (CSPV) and
cox-1. Amplification of 36B4 was used as a control. Lanes are the same as
in Fig. 1. The identity of the lower band in the CSPV RT-PCR is unknown
but is consistently observed in samples that are negative for the upper band
of the expected size.
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ancy is unknown but might have to do with the fact that we
used serum-free, nondifferentiating media in our experi-
ments. In addition, Nees et al. used cervical keratinocytes
and we used foreskin keratinocytes. Nevertheless, both
studies indicate that HPV-16 modulates expression of dif-
ferentiation-associated genes. The life cycle of HPV is
closely associated with differentiation and expression of late
genes is not thought to occur until cells have begun to
differentiate. HPV-16 E6 and E7 delay cellular differentia-
tion and keep cells in a state of DNA synthesis even after
they have entered the suprabasal layer of the epidermis.
Thus, the downregulation of differentiation genes may aug-
ment this process and also play a role in the development of
malignancy. On the other hand, many of the genes identified
to be downregulated by E6 are normally involved in forma-
tion of the cornified envelope. Disruption of the cornified
envelope may play some role in release of mature HPV
virions during the HPV life cycle (Brown and Bryan, 2000;
Lehr et al., 2002). This hypothesis can only be addressed
using a system in which HPV-16 virions can be produced.
Other groups have shown by microarray analysis that
HPV-16 and -31 E6 and E7 can downregulate genes in-
volved in immune responses such as the interferon-regu-
lated gene Stat-1 (Chang and Laimins, 2001; Nees et al.,
2001). We did not see significant modulation of Stat-1 by
HPV-16 E6/E7 as compared to E7 in our analysis, nor did
we see modulation in E6/E7 cells as compared to vector
alone. The reason for this is unknown but, again, may have
to do with culture conditions. We did observe downregula-
tion of the interferon-inducible gene Staf50 and modulation
of several genes involved in inflammation such as Nag-1,
Cox-1, and IRAP, suggesting that E6 plays a role in regu-
lation of the immune/inflammatory response.
One interesting finding of this study was that some cel-
lular genes are differentially regulated by E6 and E7. For
example, our data suggest that E6 and E7 divergently reg-
ulate vimentin: E6 maintained or even slightly increased
vimentin levels compared to the vector control, E7 caused
vimentin downregulation, and coexpression of E6 and E7
resulted in intermediate vimentin levels. Vimentin, an in-
termediate filament protein normally expressed in mesen-
chymal cells, has been shown to be overexpressed in cer-
vical cancers (Gilles et al., 1996). Interestingly, another
gene that was differentially regulated by E6 and E7 in a
similar fashion to vimentin is MEST, a gene with homology
to the /-hydrolase family, which is also normally ex-
pressed in mesenchymal lineages (Kaneko-Ishino et al.,
1995; Sado et al., 1993). The differential regulation of
vimentin and MEST could not be attributed to p53 status as
the 8S9A10T E6 mutant also upregulated expression.
Whether differential regulation of vimentin, MEST, or any
other genes plays a role in the HPV life cycle or transfor-
mation remains to be determined. It is generally believed
that HPV-16 E6 and E7 are expressed concomitantly in cells
as they are both contained on a single transcript (Howley,
1995). There is evidence, however, that differential splicing
could be involved in modulating levels of E6 and E7 (Pim
and Banks, 1999). Thus, there is a possibility that E6 and E7
are expressed at different ratios during different stages of
the viral life cycle. Upregulation of mesenchymal-specific
genes might suggest a switch to a more mesenchymal phe-
notype in cells that express E6. This switch could be im-
portant in conversion of cells to a more malignant pheno-
type. One study, for example, indicated that vimentin is
upregulated during the course of HPV-mediated immortal-
ization (Gilles et al., 1994). It would be interesting to de-
termine if expression of genes such as vimentin are depen-
dent on levels of E6 or E7 expression. This type of study
will only become possible when good antibodies for E6 and
E7 are developed.
In summary, we have identified a number of cellular
genes that are regulated by expression of HPV-16 E6. These
genes are involved in such processes as differentiation,
cell-cycle control, and immune response. The E6-regulated
genes identified in this analysis may play a role in the HPV
life cycle and/or in HPV-mediated carcinogenesis.
Materials and methods
Cell culture
Primary cultures of human foreskin keratinocytes
(HFKs) were established from foreskin tissue obtained from
newborns. Keratinocytes were maintained in Keratinocyte-
SFM (Gibco-BRL, Rockville, MD) and cultures were sam-
pled for TRAP, protein, or RNA when approximately 80%
confluent. Primary cultures of HFKs were first infected with
a retrovirus expressing HPV-16 E7 in a pLXSH vector and
then subsequently infected with LXSN-based retroviruses
expressing wild-type HPV-16 E6, mutant 8S9A10T E6, or
mutant 118–122 E6 as previously described (Foster et al.,
1994). Identical retroviral infections were performed on two
independently derived HFK cells strains. After infection,
keratinocytes were selected in 8 g/ml hygromycin
(pLXSH-E7) or 50 g/ml neomycin (pLXSN constructs)
for 6–8 days and were subcultured at least twice prior to use
in TRAP or extraction of protein or RNA.
Telomeric repeat amplification protocol
Monolayer cultures of HFKs expressing E7 and/or mu-
tant or wild-type E6 were washed with PBS and removed
from tissue culture plates through trypsinization. Cells (2 
105) were collected and washed with PBS. Cells were col-
lected through centrifugation and cell pellets were stored at
80°C. Telomerase activity was measured using the Telo
TAGGG Telomerase PCR ELISA kit (Roche Diagnostics,
Indianapolis, IN).
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RNA isolation and purification
For microarray analyses, RNA was extracted from grow-
ing monolayer cultures using the RNAqueous-Midi large-
scale, phenol-free, total RNA isolation kit (Ambion, Inc.,
Austin, TX). Total RNA was precipitated at 20°C over-
night with 0.1 volume of ammonium acetate and two vol-
umes 100% ethanol, centrifuged at 15,000 rpm, washed
with 80% ethanol, dried by evaporation, and resuspended in
diethyl pyrocarbonate-treated water. The integrity of RNA
was analyzed by electrophoresis and samples were stored at
80°C. Total RNA for Northern or RT-PCR analyses was
extracted by a similar method or by using Tri-Reagent
(Molecular Research Center, Inc., Cincinnati, OH) follow-
ing the manufacturer’s protocol.
Oligonucleotide array analysis
Biotinylated single-stranded antisense RNA samples were
prepared for hybridization as follows. cDNA was synthesized
using the Superscript Double-Stranded cDNA Synthesis kit
(Gibco-BRL). First-strand cDNA synthesis reactions were per-
formed using 40 g of total RNA, prepared as above, and
oligo(dT) primers containing a T7 RNA polymerase promoter
sequence at the 5 end [5-GGCCAGTGAATTGTAATAC-
GACTCACTATAGGGAGGCGG(T)24-3]. Second-strand
synthesis was performed using Escherichia coli DNA poly-
merase I and ligase. The resulting double-stranded cDNA
samples were cleaned through phenol:chloroform:isoamyl-
alcohol extraction and ethanol-ammonium acetate precipi-
tation. Samples were resuspended in 13 l diethyl pyrocar-
bonate treated water. Biotin-labeled cRNA was synthesized
from 4 l of the double-stranded cDNA samples by in vitro
transcription using the BioArray High Yield RNA Tran-
script Labeling kit (Enzo Diagnostics, Inc., Farmingdale,
NY). Labeled cRNA samples were cleaned using the
RNeasy Mini kit (Qiagen, Inc., Valencia, CA) and eluted
with 25 l diethyl pyrocarbonate-treated water. Labeled
cRNA samples were fragmented to an average size of 100–
200 bases by incubating at 94°C for 35 min in a buffer
containing 40 mM Tris–acetate (pH 8.1), 100 mM KOAc,
and 30 mM MgOAc.
The array hybridization, washing, and staining proce-
dures were performed by the University of Iowa DNA
Facility according to Affymetrix protocols using 12 g
samples of labeled, fragmented cRNA on gene chips with
probes to 5600 full-length human genes (HuGeneFL Ar-
rays, Affymetrix, Inc., Santa Clara, CA). The DNA arrays
were scanned by the University of Iowa DNA Facility using
a confocal scanner manufactured for Affymetrix by Molec-
ular Dynamics.
Data collected in each hybridization experiment were
processed using the GENECHIP software supplied with the
Affymetrix instrumentation system. To minimize false pos-
itives, we used cutoff thresholds empirically determined to
be conservative. The change in mRNA level for any gene
was considered significant if (1) it was considered Increased
or Decreased by the Difference Call Decision Matrix algo-
rithm of the GENECHIP software, and (2) it had a fold
change of more than twofold as calculated by a Comparison
Analysis algorithm of the GENECHIP software.
RT-PCR
hTERT
Relative quantitative multiplex RT-PCR was performed
using 18S rRNA internal controls as follows. cDNA syn-
thesis reactions were performed using Ambion’s RETRO-
script kit (Ambion). Samples (2 g) of DNase I-treated total
RNA were used as the template for single-stranded cDNA
synthesis reactions primed with the random decamers in-
cluded in the RETROscript kit. Multiplex PCR reactions
were performed using one-twentieth of each reverse-tran-
scription reaction with primers for both the 18S rRNA
internal control and the gene of interest. To avoid saturation
or plateau effect, the linear range of amplification efficiency
for each gene studied was determined by comparing the
amplification products from identical reactions removed
from the thermalcycler every other cycle. The number of
cycles that yielded an amplification-efficiency in the middle
of this linear range was used in subsequent reactions. To
ensure accurate quantification, the amplification efficiency
of the 18S internal control was modulated using Quantum-
RNA 18S Internal Standards Primers and Competimers
(Ambion) to give a product quantity similar to that of the
gene of interest. RT-PCR reaction products were separated
by agarose gel electrophoresis and stained with SYBR
Green I nucleic acid gel stain (Roche Molecular Biochemi-
cals). The primers for amplification of hTERT were forward
5-TTCCTGCACTGGCTGATGAGTGT-3 and reverse 5-
CGCTCGGCCCTCTTTTCTCTG-3 with an annealing
temperature of 57°C, yielding an amplicon of 329 bp.
Cox-1, CSPV, 36B4
For RT-PCR of Cox-1, chondroitin sulfate proteogly-
can versican (CSPV), and the internal control, 36B4,
cDNA was synthesized from 1 g of total RNA using the
RETROScript kit (Ambion) according to the manufactur-
er’s protocol using random decamers. The following
primers and conditions were used for RT-PCR amplifi-
cation of the indicated genes: Cox-1, forward primer
5-ACCAGGGCATCTGTGTCC-3, reverse primer 5-
CCAGCTGATGTAGTCATGTG-3, annealing tempera-
ture of 50°C, 30 cycles, 295-bp product; CSPV, forward
primer 5-CAAGCATCCTGTCTCACGAA-3, reverse
primer 5-ACATGTTCGCCATTTTAGGG-3, annealing
temperature of 52°C, 33 cycles, 600-bp product; 36B4,
forward primer 5-GGCCAGCTGGAAGTCCAACT-3,
reverse primer 5-CCATCAGCACCACAGCCTTC-3,
annealing temperature of 54°C, 23 cycles, 150-bp prod-
uct (Bieche et al., 2000). PCR was performed using
Ambion’s SuperTaq.
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Northern analysis
Northern probes for vimentin, SPRR1A, and MEST were
generated by cloning a 600-bp RT-PCR product into
pGEM-T (Promega), releasing the insert by restriction di-
gestion, and isolating the insert by gel extraction using the
Qiagen gel extraction kit. The primers used to generate the
probes were as follows: vimentin, forward primer 5-
GCAAAACACCCTGCAATCTT-3, reverse primer 5-
TGGCAATCTCAATGTCAAGG-3; SPRR1A, forward
primer 5-ACACAGCCCATTCTGCTCCG-3, reverse
primer 5-TGCAAAGGAGCGATTATGATT-3; MEST,
forward primer 5-TCAAAGATGGAGGTGTGCTG-3, re-
verse primer 5-CTCCTGCTGGCTTCTTCCTA-3. The
probe for p21 was a 2.1-kb insert released by BamHI di-
gestion of a plasmid kindly provided by Guy Adair (M.D.
Anderson). For Northern blotting, 20 g total RNA was
separated on a denaturing formaldehyde gel, 1.2% agarose.
RNA was transferred to either Zeta Probe (Bio-Rad) or
Hybond-XL (Amersham) membranes and hybridization was
performed following manufacturers’ protocols. Probe DNA
was labeled with [32P]dCTP using either HotPrime (Gen-
Hunter Corp.) or the MegaPrime (Amersham-Pharmacia)
DNA labeling kits according to the manufacturers’ proto-
cols. Membranes were hybridized overnight, washed, and
exposed to film for autoradiography.
Western blot protein analysis
Western blot analyses of cellular protein levels were
performed as previously described (Foster et al., 1994)
using 30 g of each protein lysate. Monoclonal antibodies
were obtained from the following sources: p53, vimentin,
and actin (Santa Cruz Biotechnology, Inc.), Stat1 (Cell
Signal Technologies), and p21 (Pharmingen).
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